Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$29.09 USD

29.09
25,001,151

+0.12 (0.41%)

Updated Sep 27, 2024 04:02 PM ET

After-Market: $29.09 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Erasca (ERAS) Inks Deal With Pfizer for Colorectal Cancer Study

by Zacks Equity Research

Erasca (ERAS) signs an agreement with Pfizer for a clinical study, which will evaluate ERAS-007 in combination with encorafenib and cetuximab for BRAF V600E-mutant metastatic colorectal cancer.

Novavax (NVAX) Begins Clinical Study on COVID/Flu Combo Jab

by Zacks Equity Research

Novavax (NVAX) starts enrolling patients in a phase I/II study to evaluate a combination of its COVID vaccine and seasonal influenza vaccine.

Pfizer (PFE) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Pfizer (PFE) closed at $46.51 in the latest trading session, marking a -0.51% move from the prior day.

Sweta Killa headshot

Tap the Nasdaq Rally With These Two Leveraged ETFs

by Sweta Killa

Investors could easily tap the bullish trend by considering a near-term long on the Nasdaq Index with the help of ETFs.

Ascendis (ASND) Seeks FDA Nod for New Immunotherapy Study

by Zacks Equity Research

Ascendis (ASND) plans to develop a sustained-release immunotherapy to treat advanced cancer developed using its TransCon platform.

Merck's (MRK) Keytruda Gets Nod for Expanded Use in China

by Zacks Equity Research

Merck's (MRK) Keytruda gets approval in combination with chemotherapy in the first-line setting for advanced esophageal and GEJ cancer in China based on data from the phase III KEYNOTE-590 study.

Moderna (MRNA) Inks Deal to Develop Ultra-Rare Disease Therapy

by Zacks Equity Research

Moderna (MRNA) inks a collaboration deal with the Institute for Life Changing Medicines to develop a free of charge mRNA-based therapy to treat Crigler-Najjar Syndrome type 1, an ultra-rare disease.

Zacks Industry Outlook Highlights: Johnson & Johnson, Roche, Pfizer and AstraZeneca

by Zacks Equity Research

Zacks Industry Outlook Highlights: Johnson & Johnson, Roche, Pfizer and AstraZeneca

Kinjel Shah headshot

4 Big Drugmaker Stocks to Watch Out For as Recovery Gains Steam

by Kinjel Shah

Most Large Cap Pharmaceuticals industry players' Q2 results were strong. Regulatory/pipeline updates related to COVID-19 medicines/vaccines continue to take center stage. JNJ, RHHBY, PFE and AZN are worth retaining in your portfolio.

Moderna (MRNA) Seeks Authorization for Booster Dose in Europe

by Zacks Equity Research

Moderna (MRNA) is developing a booster dose of its COVID-19 vaccine, mRNA-1273, for enhancing protection against infection in individuals.

Celsion (CLSN) COVID Vaccine Effective in Pre-Clinical Studies

by Zacks Equity Research

Celsion (CLSN) announces data from pre-clinical studies for its investigational vaccine platform as a potential treatment for COVID-19.

Adamis (ADMP) Begins Dosing in COVID Oral Antiviral Study

by Zacks Equity Research

Adamis (ADMP) starts dosing patients in phase II/III study to evaluate its oral investigational antiviral for the treatment of COVID-19.

Kinjel Shah headshot

Pharma Stock Roundup: New Warning Order by FDA for JAK Drugs, & Pipeline Updates

by Kinjel Shah

FDA requires a heart-risk warning on the label of JAK inhibitor medicines, Pfizer's (PFE) Xeljanz, Lilly's (LLY) Olumiant, and AbbVie's (ABBV) Rinvoq. Sanofi, Merck and others give pipeline updates.

Sweta Killa headshot

5 Niche ETFs Sizzling This Summer

by Sweta Killa

Wall Street has been shining bright this summer thanks to upbeat corporate earnings, renewed optimism in a sustained economic recovery, and the Fed's dovish view.

Pfizer (PFE) Begins Study on RSV Vaccine in Older Adults

by Zacks Equity Research

Pfizer (PFE) starts a phase III study which will evaluate its respiratory syncytial virus vaccine candidate, RSVpreF in adults aged 60 years and above.

Sweta Jaiswal, FRM headshot

5 Top-Ranked ETFs That Outperformed in August

by Sweta Jaiswal, FRM

Let's take a look at some top-ranked ETFs that outperformed Wall Street in August.

Merck (MRK) Begins Molnupiravir Study for COVID Prevention

by Zacks Equity Research

Merck (MRK) starts enrolling participants in phase III study to evaluate its oral investigational antiviral for the prevention of COVID-19.

AbbVie (ABBV) Stock Down as FDA Issues New Warning for Rinvoq

by Zacks Equity Research

FDA requires a heart-risk warning on the label of AbbVie's (ABBV) JAK inhibitor medicine, Rinvoq.

Sweta Killa headshot

4 Small-Cap ETFs & Stocks to Explode Higher

by Sweta Killa

With renewed optimism over a sustained economic recovery and robust corporate earnings growth, the small-cap space is set to explode higher.

Moderna (MRNA) Gives First COVID Jab Booster Data to the FDA

by Zacks Equity Research

Moderna's (MRNA) booster dose of COVID-19 vaccine elicits antibody levels that were much higher than that seen after the two-dose primary schedule.

Sweta Killa headshot

5 Tech Stocks Leading the Latest Nasdaq ETF Rally

by Sweta Killa

Most of the rally was powered by renewed buying in the high-growth tech giants as tapering fears ease as well as optimism over a sustained economic recovery.

Kinjel Shah headshot

FDA Orders Warnings on Pfizer, Lilly, AbbVie JAK Drug Labels

by Kinjel Shah

The FDA requires a heart-risk warning on the label of JAK inhibitor medicines, Pfizer's (PFE) Xeljanz/Xeljanz XR, Lilly (LLY)/Incyte's (INCY) Olumiant, and AbbVie's (ABBV) Rinvoq.

Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Pfizer (PFE) closed at $46.04 in the latest trading session, marking a -0.07% move from the prior day.

Sweta Killa headshot

5 Sector ETFs That Beat the Market in August

by Sweta Killa

Most of the rally was powered by a huge vaccination drive, upbeat corporate earnings and the Fed's dovish comments that have renewed optimism for sustained global economic recovery.

J&J's (JNJ) HIV Vaccine Study in Young African Women Fails

by Zacks Equity Research

J&J's (JNJ) mid-stage study shows HIV vaccine fails to provide enough protection against HIV in young women in Africa.